Abeona Therapeutics Emerges in Dystrophic Epidermolysis Bullosa Market with ZEVASKYN Approval#United_States#Las_Vegas#ZEVASKYN#Abeona_Therapeutics#Dystrophic_Epidermolysis_Bullosa
Abeona Therapeutics Emerges in Dystrophic Epidermolysis Bullosa Market with ZEVASKYN Approval
Abeona Therapeutics has made a key entry into the dystrophic epidermolysis bullosa (DEB) market by gaining FDA approval for its innovative gene therapy, ZEVASKYN, aimed at treating RDEB.
third-news.com
May 22, 2025 at 9:41 PM
Abeona Therapeutics Emerges in Dystrophic Epidermolysis Bullosa Market with ZEVASKYN Approval#United_States#Las_Vegas#ZEVASKYN#Abeona_Therapeutics#Dystrophic_Epidermolysis_Bullosa